Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay

被引:15
作者
Abdelhamed, AM
Kelley, CM
Miller, TG
Furman, PA
Cable, EE
Isom, HC
机构
[1] Penn State Coll Med, Milton S Hershey Med Ctr, Dept Microbiol & Immunol, Hershey, PA 17033 USA
[2] Penn State Coll Med, Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA 17033 USA
[3] Triangle Pharmaceut, Durham, NC 27707 USA
关键词
D O I
10.1128/AAC.47.1.324-336.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In this study, we used a quantitative assay to measure the concentration-dependent effects of antivirals on extracellular hepatitis B virus (HBV) DNA as well as on different cytoplasmic and nuclear forms of HBV DNA that participate in HBV replication. HBV recombinant baculovirus, which efficiently delivers the HBV genome to HepG2 cells, was used for this study because (i) antivirals can be administered prior to initiation of HBV infection or after HBV infection and (ii) sufficiently high HBV replication levels are achieved that HBV covalently closed circular (CCC) DNA can be easily detected and individual HBV DNA species can be quantitatively analyzed separately from total HBV DNA. The results showed that the levels of HBV replicative intermediate and extracellular DNA decreased in a concentration-dependent fashion following antiviral treatment. The 50% effective concentration (EC50) and EC90 values and the Hill slopes differed for the different HBV DNA species analyzed. The data clearly indicated that (i) nuclear HBV DNAs are more resistant to antiviral therapy than cytoplasmic or extracellular HBV DNAs and (ii) nuclear HBV CCC DNA is more resistant than the nuclear relaxed circular form. This report presents the first in vitro comparison of the effects of two antivirals administered prior to initiation of HBV infection and the first thorough in vitro quantitative study of concentration-dependent antiviral effects on HBV CCC DNA.
引用
收藏
页码:324 / 336
页数:13
相关论文
共 57 条
[1]   Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment [J].
Abdelhamed, AM ;
Kelley, CM ;
Miller, TG ;
Furman, PA ;
Isom, HC .
JOURNAL OF VIROLOGY, 2002, 76 (16) :8148-8160
[2]  
Aguesse-Germon S, 1998, ANTIMICROB AGENTS CH, V42, P369
[3]   INVITRO INFECTION OF WOODCHUCK HEPATOCYTES WITH WOODCHUCK HEPATITIS-VIRUS AND GROUND-SQUIRREL HEPATITIS-VIRUS [J].
ALDRICH, CE ;
COATES, L ;
WU, TT ;
NEWBOLD, J ;
TENNANT, BC ;
SUMMERS, J ;
SEEGER, C ;
MASON, WS .
VIROLOGY, 1989, 172 (01) :247-252
[4]   Baculovirus-mediated gene transfer into mammalian cells [J].
Boyce, FM ;
Bucher, NLR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (06) :2348-2352
[5]  
Chu CK, 1998, ANTIVIR THER, V3, P113
[6]   USE OF 2'-FLUORO-5-METHYL-BETA-L-ARABINOFURANOSYLURACIL AS A NOVEL ANTIVIRAL AGENT FOR HEPATITIS-B VIRUS AND EPSTEIN-BARR-VIRUS [J].
CHU, CK ;
MA, TW ;
SHANHMUGANATHAN, K ;
WANG, CG ;
XIANG, YJ ;
PAI, SB ;
YAO, GQ ;
SOMMADOSSI, JP ;
CHENG, YC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (04) :979-981
[7]   In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks [J].
Cullen, JM ;
Smith, SL ;
Davis, MG ;
Dunn, SE ;
Botteron, C ;
Cecchi, A ;
Linsey, D ;
Linzey, D ;
Frick, L ;
Paff, MT ;
Goulding, A ;
Biron, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2076-2082
[8]  
DANE DS, 1970, LANCET, V1, P695
[9]   Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-β-2′,3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA [J].
Delaney, WE ;
Miller, TG ;
Isom, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :2017-2026
[10]   Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant Baculovirus [J].
Delaney, WE ;
Isom, HC .
HEPATOLOGY, 1998, 28 (04) :1134-1146